A reliable nitroxoline supplier should provide more than a polished certificate. Verify chemical identity through orthogonal testing, such as HPLC, LC-MS, and NMR. The certificate should show assay, impurity limits, residual solvents, water content, and test methods. Ask for at least three recent batch records. Compare results, not only template language. Small differences in impurity profiles can affect cell-based anticancer experiments.

Manufacturing controls matter. Check whether the facility follows applicable GMP principles, documented change control, deviation review, and validated analytical procedures. The FDA’s 2019 Drug Shortages Task Force report stated that about 80% of active pharmaceutical ingredients used in United States medicines came from overseas sources. This makes site transparency and supply continuity practical concerns. Request the manufacturing address, audit history, batch traceability, and storage conditions. Cold-chain claims need temperature logs, not promises.

Regulatory documentation should match the intended use. Nitroxoline’s legal status and approved indications vary by jurisdiction, so suppliers must provide accurate product classification and shipping documents. WHO Technical Report Series No. 1033, Annex 4, emphasizes data integrity, traceability, and controlled laboratory records. Those principles apply during supplier qualification. I once treated a recent CoA as sufficient evidence; that was a weak shortcut. A better review checks raw chromatograms, reference standards, retest dates, and complaint history. Still, paperwork cannot replace independent testing. A qualified laboratory should confirm identity and purity before costly oncology studies begin.